SCHEMBL458360

SCHEMBL458360

CCc1c[c]ccc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457593 0.83
SCHEMBL58401 0.82 GABRA1 (0.33)
SCHEMBL10458945 0.81 TAAR1 (0.31)
SCHEMBL27460611 0.80 GABRA1 (0.32)
SCHEMBL62016 0.78
SCHEMBL455192 0.78
SCHEMBL29042076 0.78
SCHEMBL18322544 0.78
SCHEMBL11716554 0.78
SCHEMBL1954797 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114181148-A 'on-off' type fluorescent probe, preparation method and application thereof 东北农业大学 2022-03-15 CN claimed
EP-1401829-B1 NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS MICROBIOTIX INC (US) 2012-08-22 EP claimed
CN-101287734-B 2-amino-7, 8-dihydro-6H-pyrido [4,3-d ] pyrimidin-5-ones NOVARTIS AG 2011-07-20 CN claimed
EP-1928875-B1 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same NOVARTIS AG (CH) 2011-06-29 EP claimed
CN-101983191-A Oxim derivatives as hsp90 inhibitors TAKEDA PHARMACEUTICAL 2011-03-02 CN claimed
EP-2252595-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP claimed
US-7671059-B2 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones NOVARTIS AG (CH) 2010-03-02 US claimed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US claimed
WO-2009097578-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-06 WO claimed
CN-101287734-A 2-amino-7, 8-dihydro-6H-pyrido [4, 3-d ] pyrimidin-5-ones NOVARTIS AG (CH) 2008-10-15 CN claimed
EP-1928875-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES Novartis AG (CH) 2008-06-11 EP claimed
CN-101198596-A 2-amino-quinaz0lin-5-ones as HSP90 inhibitors useful in treating proliferation diseases NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-06-11 CN claimed
EP-1885701-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES Novartis Vaccines and Diagnostics, Inc. (US) 2008-02-13 EP claimed
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones CHIRON CORPORATION 2007-05-31 US claimed
WO-2007041362-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES NOVARTIS AG (CH) 2007-04-12 WO claimed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US claimed
WO-2006113498-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-10-26 WO claimed
EP-1199310-B1 PROCESS FOR THE PREPARATION OF CONDENSED PHOSPHORIC ESTERS DAIHACHI CHEM IND (JP) 2003-11-05 EP claimed
US-20030114445-A1 N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-19 US claimed
WO-2003011297-A1 N3-SUBSTITUTED 6-ANILINOPYRIMIDINES AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS UNIVERSITY OF MASSACHUSETTS (US) 2003-02-13 WO claimed